由一家美国公司Introgen 设计的Advexin目标在于攻克头颈部癌症；位于伦敦的Ark Therapeutics生产出的Cerepro将目标对准了恶性胶质瘤，一种致死性的脑肿瘤。
Advexin, devised by Introgen, an American company, is aimed at combating head and neck cancer; and London-based Ark Therapeutics’ Cerepro targets malignant glioma, a fatal brain tumour.
公司也将在下个月的美国临床肿瘤学会的一次会议中发布他们的临床研究结果。
The company plans to present study results on Cervarix next month at a meeting of the American Society of Clinical Oncology.
应用推荐